Phase 2: Active Initiatives
Phase 2 launched in 2026 and is the consortium's current, active phase. This page reflects ongoing work and will be updated as it progresses.
What Phase 2 Is Working Toward
Building on Phase 1's foundational frameworks, Phase 2 expands the consortium's membership and moves from framework development toward broader adoption, refinement, and real-world application.
Executive Committee
Governance emphasizes transparency, inclusivity, and the cross-sector collaboration required to responsibly advance AI innovation in regulated environments.
Christina Mack, Ph.D. is Senior Vice President of Applied AI Science within the AI and Technology Solutions (ATS) business, where she is responsible for driving scientific and technical innovation across the organization that has direct impact on patient health. Dr. Mack also leads the IQVIA Surveillance and Agile Analytics Team, which partners with biopharma and elite sports organizations such as NFL and NBA to prevent disease, reduce injuries and improve population health and safety.
In addition to this role, she serves as Chief Scientific Officer of IQVIA's Real World Evidence business, focused on applying advanced analytics and data science — including artificial intelligence — to improve population health, strengthen clinical evidence, and support regulatory decision-making.
Leon Rozenblit is a nationally recognized thought leader at the intersection of clinical research informatics and AI governance. As Co-Founder and Executive Committee member of the DCI Network at Beth Israel Deaconess Medical Center, Harvard Medical School, he has co-organized two AI governance conferences and published peer-reviewed research on multi-stakeholder approaches to responsible AI in healthcare.
A pioneer of "registry science," he has led dozens of national-scale registry programs and brings an interdisciplinary perspective spanning informatics, cognitive science, statistics, and law to bridge IT, scientific, and senior executive teams. He also advises health technology startups as Entrepreneur in Residence at Yale Ventures.
An influential and data-driven executive professional with a robust background in the Pharmaceutical and Public Health sectors, bringing a unique blend of expertise in leading digital transformation initiatives and leveraging data to guide corporations through complex business changes.
Recognized as a thought leader and industry expert in the data, digital health, and AI ecosystem, Sridevi excels at understanding industry trends and developing strategic perspectives to guide digital health and AI partnerships and investments. She brings high-level analytical skills and deep expertise in drug development, clinical, safety and regulatory processes, data management, digital innovation, and governance.
Stephanie Rosner serves as Senior Scientific Program Manager for Artificial Intelligence at DIA, where she leads the development and coordination of the DIA AI Consortium. She works closely with co-chairs, working group leads, and member organizations to advance trustworthy AI frameworks across the life sciences industry.
Carrie Nielson is a Director of Epidemiology at Gilead Sciences, where she focuses on regulatory policy for RWE and on rigorous observational research methods that support reliable evidence generation.
She collaborates with industry, academic, and regulatory colleagues, including through the DIA Artificial Intelligence Consortium, helping align on AI use-case development, risk-proportionate validation approaches, and defensible oversight and documentation models. Her work centers on translating emerging regulatory expectations into practical, inspection-ready systems and procedures that enable sound adoption of RWE and AI in drug development contexts.
Bala heads VB Insights, an advisory firm for the Healthcare and Life Sciences sector. Bala brings over 36 years of experience. During his long tenure, he has been responsible for the introduction of Web, document management, global team collaboration, and regulatory information management applications to large pharma.
Until recently, Bala was Head of the Healthcare and Life Sciences at Orion Innovation. As an entrepreneur and a thought leader, he has been involved in initiatives to transform regulatory affairs from a document-centric function to a data-driven function. Bala has been associated with DIA for more than 17 years, leading DIA RIM Reference Model workstream and DIA AI Consortium Regulatory Frameworks and Terminology workstream.
Active Working Groups
Meeting Schedule
Deliverables in Progress
Outputs currently underway for Phase 2.
Participating Organizations
36 organizations across regulators, industry, academia, and technology sectors currently participate in Phase 2.
Consortium in Action
Moments from AI Consortium sessions and meetings at the DIA Global Annual Meeting.
